Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
103819136 | 10381913 | 6 | F | 20100412 | 20160830 | 20140813 | 20160908 | EXP | JP-009507513-1112USA03347 | MERCK | 75.00 | YR | M | Y | 0.00000 | 20160908 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
103819136 | 10381913 | 1 | PS | ISENTRESS | RALTEGRAVIR POTASSIUM | 1 | Oral | 800 MG, QD, DIVIDED DOSE FREQUENCY UNKNOWN | 22145 | 800 | MG | TABLET | QD | ||||||
103819136 | 10381913 | 2 | SS | PREZISTA | DARUNAVIR ETHANOLATE | 1 | Oral | 800 MG, QD, | 28800 | MG | 0 | 800 | MG | TABLET | QD | ||||
103819136 | 10381913 | 3 | SS | VALIXA | VALGANCICLOVIR | 1 | Oral | 900 MG, BID | 43200 | MG | 0 | 900 | MG | TABLET | BID | ||||
103819136 | 10381913 | 4 | SS | VALIXA | VALGANCICLOVIR | 1 | Oral | 900 MG, QD | 43200 | MG | 0 | 900 | MG | TABLET | QD | ||||
103819136 | 10381913 | 5 | I | ADOAIR | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 500 MICROGRAM, BID | 0 | 500 | UG | INHALATION POWDER | BID | ||||||
103819136 | 10381913 | 6 | I | ADOAIR | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 250 MICROGRAM, BID | 0 | 250 | UG | INHALATION POWDER | BID | ||||||
103819136 | 10381913 | 7 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD; DIVIDED DOSE FREQUENCY UNKNOWN | 1593 | DF | Y | 0 | 1 | DF | TABLET | QD | |||
103819136 | 10381913 | 8 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD; DIVIDED DOSE FREQUENCY UNKNOWN | 1593 | DF | Y | 0 | 1 | DF | TABLET | QD | |||
103819136 | 10381913 | 9 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD; DIVIDED DOSE FREQUENCY UNKNOWN | 1593 | DF | Y | 0 | 1 | DF | TABLET | QD | |||
103819136 | 10381913 | 10 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QOD | 1593 | DF | Y | 0 | 1 | DF | TABLET | QOD | |||
103819136 | 10381913 | 11 | I | NORVIR | RITONAVIR | 1 | Oral | 100 MG, QD; DIVIDED DOSE FREQUENCY UNKNOWN, FORMULATION: POR | 3600 | MG | 0 | 100 | MG | QD | |||||
103819136 | 10381913 | 12 | SS | NORVIR | RITONAVIR | 1 | Oral | 100 MG, QD, DIVIDED DOSE FRQUENCY UNKNOWN | 89200 | MG | 0 | 100 | MG | CAPSULE | QD | ||||
103819136 | 10381913 | 13 | C | EPIVIR | LAMIVUDINE | 1 | Oral | 300 MG, QD | 150900 | MG | U | 0 | 300 | MG | TABLET | QD | |||
103819136 | 10381913 | 14 | C | ZERIT | STAVUDINE | 1 | Oral | 60 MG; DIVIDED DOSE FREQUENCY UNKNOWN | U | 0 | 60 | MG | CAPSULE | QD | |||||
103819136 | 10381913 | 15 | C | REYATAZ | ATAZANAVIR SULFATE | 1 | Oral | 300 MG, DIVIDED DOSE FREQUENCY UNKNOWN | U | 0 | 300 | MG | CAPSULE | QD | |||||
103819136 | 10381913 | 16 | C | BAKTAR | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | TABLET | QD | |||||
103819136 | 10381913 | 17 | C | DEPAS | ETIZOLAM | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | TABLET | QD | |||||
103819136 | 10381913 | 18 | C | LYRICA | PREGABALIN | 1 | Oral | 75 MG, BID; FORMULATION POR | U | 0 | 75 | MG | BID |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
103819136 | 10381913 | 1 | HIV infection |
103819136 | 10381913 | 2 | HIV infection |
103819136 | 10381913 | 3 | Cytomegalovirus infection |
103819136 | 10381913 | 5 | Chronic obstructive pulmonary disease |
103819136 | 10381913 | 6 | Emphysema |
103819136 | 10381913 | 7 | HIV infection |
103819136 | 10381913 | 11 | HIV infection |
103819136 | 10381913 | 12 | HIV infection |
103819136 | 10381913 | 13 | HIV infection |
103819136 | 10381913 | 14 | HIV infection |
103819136 | 10381913 | 15 | HIV infection |
103819136 | 10381913 | 16 | Antifungal prophylaxis |
103819136 | 10381913 | 17 | Insomnia |
103819136 | 10381913 | 18 | Neuralgia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
103819136 | 10381913 | OT |
103819136 | 10381913 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
103819136 | 10381913 | CD4 lymphocytes decreased | |
103819136 | 10381913 | Cardiac failure | |
103819136 | 10381913 | Drug interaction | |
103819136 | 10381913 | Duodenal ulcer | |
103819136 | 10381913 | Gastrooesophageal reflux disease | |
103819136 | 10381913 | Glucose tolerance impaired | |
103819136 | 10381913 | Lymphocyte count decreased | |
103819136 | 10381913 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
103819136 | 10381913 | 1 | 20100412 | 0 | ||
103819136 | 10381913 | 2 | 20130426 | 20130531 | 0 | |
103819136 | 10381913 | 3 | 20130611 | 20130701 | 0 | |
103819136 | 10381913 | 4 | 20130702 | 20130707 | 0 | |
103819136 | 10381913 | 5 | 201004 | 20140807 | 0 | |
103819136 | 10381913 | 6 | 20140808 | 0 | ||
103819136 | 10381913 | 7 | 20071102 | 20081113 | 0 | |
103819136 | 10381913 | 8 | 20100412 | 20130425 | 0 | |
103819136 | 10381913 | 9 | 20130601 | 20131114 | 0 | |
103819136 | 10381913 | 10 | 20131115 | 0 | ||
103819136 | 10381913 | 11 | 20130426 | 20130531 | 0 | |
103819136 | 10381913 | 12 | 20071102 | 20100411 | 0 | |
103819136 | 10381913 | 13 | 20081125 | 20100411 | 0 | |
103819136 | 10381913 | 14 | 20081125 | 20100411 | 0 | |
103819136 | 10381913 | 15 | 20071102 | 20100411 | 0 | |
103819136 | 10381913 | 17 | 20130426 | 0 |